# A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects

> **NCT05380934** · PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 63 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** TQH3821 tablets
- **DRUG:** TQH3821 tablets (Placebo)
- **DRUG:** Methotrexate tablets

## Key facts

- **NCT ID:** NCT05380934
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-29
- **Primary completion:** 2023-05-20
- **Final completion:** 2023-05-20
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05380934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05380934, "A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05380934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*